INDEPENDENCE CONTRACT DRILLI (ICD) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:ICD - US4534156066 - Common Stock
0.5858 USD
-0.06 (-9.88%)
0.555 USD
-0.03 (-5.26%)
ICD gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 62 industry peers in the Energy Equipment & Services industry. ICD may be in some trouble as it scores bad on both profitability and health. ICD is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year ICD has reported negative net income.
ICD had a positive operating cash flow in the past year.
In the past 5 years ICD always reported negative net income.
Of the past 5 years ICD 4 years had a positive operating cash flow.
1.2 Ratios
With a Return On Assets value of -15.80%, ICD is not doing good in the industry: 92.06% of the companies in the same industry are doing better.
The Return On Equity of ICD (-37.58%) is worse than 87.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.8% | ||
| ROE | -37.58% | ||
| ROIC | N/A |
ROA(3y)-13.85%
ROA(5y)-15.34%
ROE(3y)-28.45%
ROE(5y)-28.56%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Operating Margin of ICD has grown nicely.
With a decent Gross Margin value of 32.59%, ICD is doing good in the industry, outperforming 65.08% of the companies in the same industry.
ICD's Gross Margin has improved in the last couple of years.
ICD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 32.59% |
OM growth 3YN/A
OM growth 5Y66.25%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.54%
GM growth 5Y2.72%
2. Health
2.1 Basic Checks
ICD does not have a ROIC to compare to the WACC, probably because it is not profitable.
ICD has more shares outstanding than it did 1 year ago.
ICD has more shares outstanding than it did 5 years ago.
ICD has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -1.26, we must say that ICD is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.26, ICD is doing worse than 88.89% of the companies in the same industry.
ICD has a debt to FCF ratio of 10.37. This is a negative value and a sign of low solvency as ICD would need 10.37 years to pay back of all of its debts.
ICD has a Debt to FCF ratio (10.37) which is in line with its industry peers.
ICD has a Debt/Equity ratio of 1.08. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.08, ICD is not doing good in the industry: 79.37% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.08 | ||
| Debt/FCF | 10.37 | ||
| Altman-Z | -1.26 |
ROIC/WACCN/A
WACC2.02%
2.3 Liquidity
ICD has a Current Ratio of 1.33. This is a normal value and indicates that ICD is financially healthy and should not expect problems in meeting its short term obligations.
ICD's Current ratio of 1.33 is on the low side compared to the rest of the industry. ICD is outperformed by 79.37% of its industry peers.
ICD has a Quick Ratio of 1.28. This is a normal value and indicates that ICD is financially healthy and should not expect problems in meeting its short term obligations.
ICD has a worse Quick ratio (1.28) than 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.33 | ||
| Quick Ratio | 1.28 |
3. Growth
3.1 Past
The earnings per share for ICD have decreased strongly by -662.07% in the last year.
Looking at the last year, ICD shows a very negative growth in Revenue. The Revenue has decreased by -21.60% in the last year.
Measured over the past years, ICD shows a quite strong growth in Revenue. The Revenue has been growing by 8.06% on average per year.
EPS 1Y (TTM)-662.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-942.86%
Revenue 1Y (TTM)-21.6%
Revenue growth 3Y36.07%
Revenue growth 5Y8.06%
Sales Q2Q%-23.12%
3.2 Future
The Earnings Per Share is expected to decrease by -46.50% on average over the next years. This is quite bad
ICD is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -8.70% yearly.
EPS Next Y-146.84%
EPS Next 2Y-46.5%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-20.87%
Revenue Next 2Y-8.7%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
ICD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ICD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ICD is valued a bit cheaper than 74.60% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ICD indicates a rather cheap valuation: ICD is cheaper than 100.00% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 0.54 | ||
| EV/EBITDA | 4.69 |
4.3 Compensation for Growth
A cheap valuation may be justified as ICD's earnings are expected to decrease with -46.50% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-46.5%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for ICD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.5858
-0.06 (-9.88%)
Chartmill FA Rating
GICS SectorEnergy
GICS IndustryGroupEnergy
GICS IndustryEnergy Equipment & Services
Earnings (Last)
Earnings (Next)
Inst Owners0.01%
Inst Owner Change0%
Ins Owners75.82%
Ins Owner Change0%
Market Cap8.92M
Revenue(TTM)179.95M
Net Income(TTM)-59.25M
Analysts80
Price Target3.57 (509.42%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-26.38%
Min EPS beat(2)-50.58%
Max EPS beat(2)-2.18%
EPS beat(4)0
Avg EPS beat(4)-48.02%
Min EPS beat(4)-115.7%
Max EPS beat(4)-2.18%
EPS beat(8)4
Avg EPS beat(8)27.37%
EPS beat(12)5
Avg EPS beat(12)-68.42%
EPS beat(16)9
Avg EPS beat(16)-49.21%
Revenue beat(2)2
Avg Revenue beat(2)6.69%
Min Revenue beat(2)2.48%
Max Revenue beat(2)10.9%
Revenue beat(4)3
Avg Revenue beat(4)3.1%
Min Revenue beat(4)-3.06%
Max Revenue beat(4)10.9%
Revenue beat(8)6
Avg Revenue beat(8)2.51%
Revenue beat(12)8
Avg Revenue beat(12)2.8%
Revenue beat(16)9
Avg Revenue beat(16)0.49%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-48.55%
EPS NQ rev (3m)-25.02%
EPS NY rev (1m)-36.74%
EPS NY rev (3m)-10.78%
Revenue NQ rev (1m)-14.34%
Revenue NQ rev (3m)-18.05%
Revenue NY rev (1m)-3.15%
Revenue NY rev (3m)-5.96%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.05 | ||
| P/FCF | 0.54 | ||
| P/OCF | 0.21 | ||
| P/B | 0.06 | ||
| P/tB | 0.06 | ||
| EV/EBITDA | 4.69 |
EPS(TTM)-2.21
EYN/A
EPS(NY)-1.95
Fwd EYN/A
FCF(TTM)1.09
FCFY186.61%
OCF(TTM)2.86
OCFY487.46%
SpS11.83
BVpS10.37
TBVpS10.37
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.8% | ||
| ROE | -37.58% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 32.59% | ||
| FCFM | 9.24% |
ROA(3y)-13.85%
ROA(5y)-15.34%
ROE(3y)-28.45%
ROE(5y)-28.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5Y66.25%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.54%
GM growth 5Y2.72%
F-Score3
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.08 | ||
| Debt/FCF | 10.37 | ||
| Debt/EBITDA | 4.57 | ||
| Cap/Depr | 58.68% | ||
| Cap/Sales | 14.9% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 116% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.33 | ||
| Quick Ratio | 1.28 | ||
| Altman-Z | -1.26 |
F-Score3
WACC2.02%
ROIC/WACCN/A
Cap/Depr(3y)80.67%
Cap/Depr(5y)71.77%
Cap/Sales(3y)20.36%
Cap/Sales(5y)19.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-662.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-942.86%
EPS Next Y-146.84%
EPS Next 2Y-46.5%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-21.6%
Revenue growth 3Y36.07%
Revenue growth 5Y8.06%
Sales Q2Q%-23.12%
Revenue Next Year-20.87%
Revenue Next 2Y-8.7%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-138.99%
EBIT growth 3YN/A
EBIT growth 5Y79.64%
EBIT Next Year42.05%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y162.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2030.36%
OCF growth 3Y494.79%
OCF growth 5Y30.47%
INDEPENDENCE CONTRACT DRILLI / ICD FAQ
What is the fundamental rating for ICD stock?
ChartMill assigns a fundamental rating of 1 / 10 to ICD.
What is the valuation status of INDEPENDENCE CONTRACT DRILLI (ICD) stock?
ChartMill assigns a valuation rating of 2 / 10 to INDEPENDENCE CONTRACT DRILLI (ICD). This can be considered as Overvalued.
Can you provide the profitability details for INDEPENDENCE CONTRACT DRILLI?
INDEPENDENCE CONTRACT DRILLI (ICD) has a profitability rating of 2 / 10.
Can you provide the financial health for ICD stock?
The financial health rating of INDEPENDENCE CONTRACT DRILLI (ICD) is 1 / 10.
What is the earnings growth outlook for INDEPENDENCE CONTRACT DRILLI?
The Earnings per Share (EPS) of INDEPENDENCE CONTRACT DRILLI (ICD) is expected to decline by -146.84% in the next year.